optimizing lymphodepletion chemotherapy in car-t therapy recipients
Published 2 years ago • 313 plays • Length 4:44Download video MP4
Download video MP3
Similar videos
-
1:07
optimal lymphodepletion in car-t therapy recipients
-
2:10
optimizing car-t therapy in lbcl
-
5:17
optimizing car-t therapy
-
1:07
optimizing car-t therapy: regulating car t-cells in vivo
-
2:57
strategies to optimize car-t therapy in myeloma: bringing car-t into earlier lines
-
1:06
car-t cell therapy: current applications and how to improve treatment strategies in the future
-
1:18
the importance of lymphodepletion, an undervalued component of the car-t therapy cycle
-
3:31
the role of lymphodepletion in car t-cell therapy: current knowledge & the need for personalization
-
2:17
the role of car t-cell therapy for treating myeloma in the era of bispecific antibodies
-
1:38
challenges of car-t therapy in the real-world setting
-
0:50
improving car-t cell efficacy: optimizing car constructs and counteracting tumor escape
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
1:39
optimizing chemotherapy in aml
-
9:58
the management & optimization of car t-cell therapy in myeloma
-
1:23
moving car-t therapy to the outpatient setting
-
1:44
challenges in developing car-t therapy for aml
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics